GlassScriptPhysician profile
Robin Lynn Fordham
NPI 1902175276
$4,727.45
in general payments reported to CMS, 2019-2025
31 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,404 · 2022: $1,068 · 2023: $1,039 · 2024: $887 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,205.67 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $979.78 | 2021-2025 | Repatha, Evenity, Prolia |
| Abbvie INC. | $744.38 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $520.96 | 2021-2025 | |
| Lilly USA, LLC | $250.89 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $228.52 | 2021 | |
| Currax Pharmaceuticals LLC | $199.73 | 2023-2024 | Contrave, Nexletol, Nexlizet |
| Novo Nordisk INC | $186.77 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.81 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $155.52 | 2021-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $136.63 | 2021-2025 | Gardasil 9, M-M-R II, Verquvo |
| Pfizer INC. | $136.62 | 2021-2023 | |
| Impulse Dynamics (USA) INC. | $136.07 | 2022 | |
| Atricure, INC. | $102.69 | 2024 | |
| Amarin Pharma, INC. | $99.16 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $96.42 | 2022-2025 | Spravato |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $70.25 | 2022-2023 | Linq II |
| Glaxosmithkline, LLC. | $60.43 | 2021-2024 | Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $59.13 | 2021-2023 | Seglentis, Livalo |
| Idorsia Pharmaceuticals US INC | $51.91 | 2023-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $48.55 | 2021-2024 | Airsupra |
| Sanofi Pasteur INC. | $45.22 | 2023 | |
| Esperion Therapeutics, INC. | $40.86 | 2021 | |
| Phadia US INC. | $36.33 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.19 | 2025 | Caplyta |
| Abiomed | $22.43 | 2024 | Impella |
| Exact Sciences Corporation | $22.00 | 2023 | Cologuard Collection Kit |
| Bausch Health US, LLC | $21.39 | 2021 | |
| Scpharmaceuticals INC. | $18.00 | 2025 | |
| Sanofi-Aventis U.S. LLC | $15.29 | 2022 | |
| Itamar Medical INC | $14.41 | 2022 | |
| Horizon Therapeutics Plc | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Fordham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.